Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to “Sell”

StockNews.com lowered shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a sell rating in a research note released on Wednesday morning.

A number of other research firms also recently commented on MCRB. Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 price objective on shares of Seres Therapeutics in a report on Thursday, November 14th. JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Finally, Chardan Capital reiterated a “buy” rating and set a $1.25 price target on shares of Seres Therapeutics in a research note on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Stock Up 7.1 %

NASDAQ:MCRB opened at $0.98 on Wednesday. The company has a market cap of $167.32 million, a price-to-earnings ratio of -4.26 and a beta of 2.06. Seres Therapeutics has a 52 week low of $0.54 and a 52 week high of $2.05. The company has a fifty day simple moving average of $0.80 and a two-hundred day simple moving average of $0.90.

Institutional Investors Weigh In On Seres Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MCRB. Vanguard Group Inc. raised its holdings in shares of Seres Therapeutics by 12.1% in the 1st quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock worth $5,213,000 after purchasing an additional 729,514 shares during the period. Vontobel Holding Ltd. purchased a new stake in shares of Seres Therapeutics in the third quarter worth about $374,000. Geode Capital Management LLC grew its stake in shares of Seres Therapeutics by 22.5% in the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after buying an additional 255,014 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Seres Therapeutics by 42.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after acquiring an additional 222,771 shares in the last quarter. Finally, FMR LLC boosted its holdings in Seres Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after acquiring an additional 140,096 shares during the period. Hedge funds and other institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.